Pioglitazone, a hypoglycemic agent, has been shown to increase plasma HDL cholesterol but the mechanism is incompletely understood. We further investigated effects of pioglitazone on transcriptional regulation of apoA-I gene and functional properties of pioglitazone-induced apoA-I-containing particles. reduced the basal apoA-I promoter activities, and no additional pioglitazonesensitive elements were found within this region. Over-expression or knockdown of LRH-1, a newly identified nuclear factor with strong stimulatory effect on apoA-
INTRODUCTION
Plasma high-density lipoprotein (HDL) levels are inversely related to the development of atherosclerotic coronary heart disease [1] . The anti-atherogenic effects of HDL have been largely attributed to the ability of apoA-I-containing HDL particles to mediate cellular cholesterol efflux and thereby facilitate the removal of excess cholesterol from peripheral tissues and its delivery to the liver for elimination through reverse cholesterol transport pathway [2, 3] . In addition, HDL also enhances fibrinolysis [4] , and inhibits platelet aggregation, LDL oxidation [5] , endothelial transmigration of monocytes [6] , and pro-inflammatory cytokine-mediated expression of endothelial cell adhesion molecules [4] [5] [6] [7] . These pleotropic properties of HDL have been thought to contribute to the beneficial effects of HDL on atherosclerotic cardiovascular disease.
Glitazones (a class of thiazolidinediones agents such as pioglitazone and rosiglitazone) are anti-hyperglycemic drugs used in the treatment of type 2 diabetes. These oral anti-diabetic agents reduce blood glucose levels by sensitizing peripheral tissues to insulin [8] . In addition to improving glycemic control, glitazones also influence plasma lipid and lipoprotein levels [9] . Treatment of type 2 diabetic patients with pioglitazone consistently increased plasma HDL-cholesterol and decreased triglycerides with generally minimal to no effect on total and LDL-cholesterol [10] [11] [12] [13] . Clinically, pioglitazone's effect on HDL-cholesterol (about 10-15% elevation) is greater than that observed with statins and several fibrates, and just below that of niacin [3] .
Initially, glitazones were designed as agonistic ligands of the nuclear receptor PPARγ to enhance insulin action mainly in skeletal muscle and adipose tissues to promote glucose utilization and suppress intracellular lipolysis. PPARs (PPARα, γ, δ) are members of the nuclear receptor family, by ligand activating and heterodimerization of PPAR with retinoid X receptor (RXR) and binding to the DNA sequence in the promoter region, modulate transcription of various target genes by guest, on www.jlr.org Downloaded from involved in glucose and lipid metabolism [14] . The effects of pioglitazone to reduce triglycerides are mainly shown to be mediated by increased lipoprotein lipase expression through the activation of PPARγ, and decrease plasma apoC-III, an inhibitor for lipoprotein lipase-mediated lipolysis [15] . However, mechanisms of the effect of pioglitazone to raise HDL and apoA-I (the major protein of HDL) are incompletely understood. In initial studies, we have shown that pioglitazone did not change uptake of HDL protein and cholesterol ester, but increased apoA-I and A-II de novo synthesis, secretion, and mRNA in human hepatoblastoma cells (HepG2) [16] . These studies suggest that pioglitazone by increasing hepatic apoA-I mRNA expression increases apoA-I-containing HDL particles without influencing HDL catabolic pathway in hepatocytes.
ApoA-I is mainly synthesized in the liver and intestine, and its expression levels are highly regulated by a number of transcription factors in response to nutrients, hormones, growth factors, cytokines, and drugs such as fibrates. These transacting factors bind to the specific DNA sequence elements in the promoter region to negatively or positively modulate the transcription of apoA-I gene [17, 18] .
Functional analysis of apoAI gene promoter by mutagenesis identified that roughly three sections A, B, and C, clustering cis-acting elements, located between nucleotides -222 and -110 upstream from the transcription start site, are essential and sufficient for liver-specific expression of apoAI gene in hepatocytes [reviewed in 19] . These cis-acting elements in site A (-214 to -192) bind thyroid receptor (TR), hepatic nuclear factor-4 (HNF-4), PPARα, RARα/β, RXRα, C/EBP, ARP-1, Rev-erbα, TNFα, and IL-1, in site B (-169~-146) bind glucocorticoids, estradiol and HNF3b, and in site C (-134~-119) bind HNF-4, ARP-1. More recently, a new nuclear factor, liver receptor homolog-1 (LRH-1) with strong stimulatory effect on apoA1 gene transcription, has been identified to be located in site C [20] . Site C also has a DR-1 (direct repeat-1) sequence for binding a liver X receptor agonist TO901317 [21] . Moreover, the regulation of the hepatic expression of apoAI gene is controlled by synergistic interaction between these transcription factors [18] . The present study was designed to further investigate Human aortic endothelial cells (HAEC) were purchased from Lonza Biologics.
MATERIALS AND METHODS

Materials
The polyclonal antibodies for human apoAI and apoAII were purchased from Calbiochem. All other chemicals used were of analytical grade.
Cell culture: HepG2 cells were maintained in DMEM (Dulbecco's Modified
Eagle's Medium, DMEM) containing 10% fetal bovine serum, supplemented with 100 units/ml penicillin G, and 100 µg/ml streptomycin sulfate at 37 o C in a humidified atmosphere of 95% air, 5% CO2. HepG2 cells were incubated in the presence or absence of pioglitazone as indicated. Human monocyte THP-1 cells and human aortic endothelial cells were grown in RPMI1640 (Invitrogen) and EMB2 (Cambrex Bio ScienceWalkersville, Inc.) medium, respectively.
Immuno-precipitation and Western blotting: HepG2 cells were grown in 6 well plates until they attained 75-80% confluence. HepG2 cells were incubated with various amount of pioglitazone (0-25 µM) at 37 o C for 24-48 hr. At the termination of the incubation, culture medium was collected. 1ml sample of culture medium was used to measure apo AI secreted into the media by immuno-preciptation and Western blotting using anti human apoA-I or apoA-II antibodies.
Plasmids:
The human apoAI promoter DNA sequence (-470~+8bp, using the transcription start site as +1) was isolated by PCR amplification from human genomic DNA (ClonTech), and cloned into pGL3 (R2.1) basic vector harboring -TCT TAC GCG TGG   ACT AAA GAA GAG CAC TGG TG-3' (sense) and 5'-CGC AGA TCT CAG TCT   CTA AGC AGC CAG CTC TT-3' (anti-sense groups. One-way ANOVA analysis was used for the multiple and full set comparisons where appropriate. P value <0.05 was considered significant.
RESULTS
Pioglitazone stimulated apoAI gene transcription
Pioglitazone ( 
PPRE is required for Pioglitazone-induced apoA-I promoter activity
PPARα, but not PPARγ, is highly expressed in the liver. Agonists for PPARα, such as fenofibrate, have been shown to increase apoA-I gene expression [14] . Furthermore, these mutations abolished pioglitazone-induced apoA-I promoter activity suggesting that the PPRE is required for the effect exerted by pioglitazone [ Fig.2B ]. Similarly, a PPARα ligand and activator fenofibrate, significantly stimulates apoA1 transcription; but it did not reverse the apoA1 promoter activity when the PPRE binding site is mutated [ Fig 2C] .
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To examine whether there are additional potential pioglitazone-sensitive elements in the apoA-I promoter, we performed deletion mapping assay. Deletion of site A (-214 to -192), site B (-169 to -146), and site C (-134 to -119) reduced the apoAI promoter activity by approximately 3-, 6-, and 9 -fold, respectively, compared to the full-length promoter, indicating that elements in these regions are important in regulation of its basal transcription activities [Fig 3] . When A, B, and C each site was deleted individually, the basal promoter activities were also reduced [ Fig 4] . No significant stimulatory effect by pioglitazone was found in these experiments. These data indicate that the integrity of all of A, B, and C sites in the apoA-I promoter is crucial for its full transcription activities and no other cis-elements responding to pioglitazone were found in these regions examined.
LRH-1 is not involved in pioglitazone-induced apoA-I transcription
To further test our deletion mapping observation, we chose the liver receptor 
Pioglitazone-induced apolipoprotein A1 transcription is mainly through PPARα but not PPARγ in HepG2 cells
Reverse transcription and quantitative real-time PCR (RT-qPCR) indicated that Knockdown of PPARα eliminated pioglitazone-induced apoA1 transcription ( 
Pioglitazone-induced apoA-I production is mainly in LP-AI particles
In HepG2 cells, previously we have shown that mainly two HDL particles are secreted, including HDL particles containing apoA-I only (LP-AI) or HDL particles containing both apoAI and apoAII (LP-AI+AII) [16] . To assess the distribution of pioglitazone-induced apoA-I in these particles, we have analyzed the secreted apoAI-containing particles by immunoprecipitation and Western blotting. As shown in Figure 8 , pioglitazone (1-10 µM) mainly increased apoA-I in LP-AI particles by 1.2-1.4 folds, and to less degree, in LP-AI+AII particles by 1.1-1.2 folds [ Fig. 8 ]. These data indicate that the increased apoA1 by pioglitazone was mainly enriched in LP-AI particles.
Conditioned media from pioglitazone-treated HepG2 cells increased the inhibition of monocyte adhesion to HAEC
In previous studies, we have shown that pioglitazone-induced apoAI-containing particles were able to mediate cholesterol efflux from macrophages [16] . To To further test whether apoA1 in the CM is directly responsible for the reduced adhesion activity, we performed immunodepletion of apoA1 and compared the effects of CM containing apoA1 (CM apoA1+) and CM without apoA1 (CM apoA1-). As shown in Fig. 9 , the conditioned media without apoA1, from either the 0µM pioglitazone-treated or 10µM pioglitazone-treated HepG2 cells, reduced their ability to inhibit the adhesion (p=0.006 and p=0.016). Comparisons between groups in CM with apoA1 and control were significant (P for trend=0.001), but not significant between groups in CM without apoA1 and control. These results suggest that apoA1/apoA1-containing particles significantly contribute to the inhibitory effects on the monocyte adhesion to the endothelial cells. to understand the mechanisms of apo-AI increase by pioglitazone, using human hepatoblasoma cell line (HepG2 cells) we have previously shown that pioglitazone by increasing apoA-I mRNA levels increased the de novo synthesis and secretion of apoA-I particles in the culture medium without affecting HDL catabolic events in HepG2 cells [16] .
DISCUSSION
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Among the three synthetic glitazones with PPAR-agonist activities, pioglitazone has a much better effect on raising HDL and lowering triglycerides. The mechanism for this divergence has been suggested to be due to the ability of pioglitazone to weakly activate PPARα. In transient transfection experiments with the reporters containing 4 copies of the rat acyl-CoA oxidase PPRE, previous studies showed that pioglitazone appeared to be a weak PPARα activator via a direct binding of pioglitazone to the artificial PPRE in kidney-derived COS-1 cells
. There is one PPRE in site A of the apoA-I promoter, and furthermore PPARα expression level is much higher than PPARγ in the liver [14] . We Additionally, our findings may be useful in forming the rationale for combination therapy using pioglitazone and other HDL raising agents with different mechanisms to additively increase HDL levels in diabetic patients. 
